[{"orgOrder":0,"company":"ActualEyes","sponsor":"Arctic Vision","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Rho-associated kinase-Human corneal endothelial cells","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ActualEyes","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"ActualEyes \/ Arctic Vision","highestDevelopmentStatusID":"4","companyTruncated":"ActualEyes \/ Arctic Vision"}]

Find Clinical Drug Pipeline Developments & Deals by ActualEyes

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Arctic Vision will develop and market ActualEyes’ AE-101, for the treatment of corneal endothelial dysfunction in Greater China and South Korea. ARVN901 (AE-101) is a novel cell-injection therapy developed using cultured hCECs combined with a ROCK inhi...

                          Brand Name : AE101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 14, 2021

                          Lead Product(s) : Rho-associated kinase-Human corneal endothelial cells

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Arctic Vision

                          Deal Size : $35.0 million

                          Deal Type : Licensing Agreement

                          blank